Sentinus LLC’s AbbVie ABBV Stock Holding History

Sentinus LLC’s Portfolio ABBV Stock Details ABBV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$5.85M	Sell	23,241 -15,595	-40%	-$3.36M	0.47%	62
2026 Q1	$8.45M	Buy	38,836 +14,457	+59%	+$3.21M	0.76%	38
2025 Q4	$5.57M	Buy	24,379 +3,446	+16%	+$785K	0.54%	59
2025 Q3	$4.85M	Buy	20,933 +4,851	+30%	+$988K	1.06%	28
2025 Q2	$2.99M	Buy	16,082 +101	+0.6%	+$18.8K	0.73%	36
2025 Q1	$3.35M	Buy	15,981 +193	+1%	+$37.5K	0.94%	30
2024 Q4	$2.81M	Buy	15,788 +239	+2%	+$43.9K	0.82%	31
2024 Q3	$3.07M	Buy	15,549 +253	+2%	+$47.2K	0.92%	26
2024 Q2	$2.62M	Buy	15,296 +1,223	+9%	+$203K	0.85%	27
2024 Q1	$2.56M	Buy	+14,073	New	+$2.43M	0.9%	26
2023 Q2	$1.84M	Sell	13,694 -138	-1%	-$20.2K	0.58%	34
2023 Q1	$2.2M	Buy	13,832 +10,551	+322%	+$1.61M	0.74%	28
2022 Q4	$536K	Sell	3,281 -9,565	-74%	-$1.47M	0.31%	61
2022 Q3	$1.72M	Buy	+12,846	New	+$1.84M	1.08%	23

Other funds holding ABBV

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Sentinus LLC's ABBV Position: Q2 2026 in Review

Sentinus LLC reduced its AbbVie (ABBV) stake by 40% in Q2 2026, selling an estimated $3.36M and leaving 23,241 shares worth $5.85M. The position accounts for 0.47% of the portfolio, ranked #62.

Sentinus LLC first reported a position in ABBV in Q3 2022 and has held it in 14 quarters since. The position peaked at $8.45M in Q1 2026. 4,222 funds tracked by Wall St. Rank hold ABBV as of Q2 2026.

Sentinus LLC held 23,241 shares of AbbVie worth $5.85M as of Q2 2026.
Sentinus LLC sold 15,595 AbbVie shares in Q2 2026, an estimated $3.36M.
AbbVie made up 0.47% of Sentinus LLC's portfolio in Q2 2026, its #62 holding.
Sentinus LLC first reported a position in AbbVie in Q3 2022 and has held it in 14 quarters since.
Sentinus LLC's AbbVie position peaked at $8.45M in Q1 2026.
4,222 funds tracked by Wall St. Rank held AbbVie as of Q2 2026.

Based on Sentinus LLC's 13F filing for Q2 2026, filed 11 Aug 2026.